Siponimod
- Generic Name
- Siponimod
- Brand Names
- Mayzent 0.25 Mg Starter Pack, Mayzent
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35F3N2O3
- CAS Number
- 1230487-00-9
- Unique Ingredient Identifier
- RR6P8L282I
- Background
Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to play a role in suppressing the central nervous system infla...
- Indication
This drug is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults .
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath